Nucleoside Metabolic Inhibitor [EPC]

202703 reported adverse events

Drugs of this class: FLUOROURACIL DECITABINE AZACITIDINE CAPECITABINE CYTARABINE CLOFARABINE NELARABINE (DAUNORUBICIN AND CYTARABINE) LIPOSOME CEDAZURIDINE AND DECITABINE GEMCITABINE PENTOSTATIN

These side effects are most commonly reported by patients taking drugs of the Nucleoside Metabolic Inhibitor [EPC] class:

#	Side effect	Count
0	DIARRHOEA	18604
1	DEATH	15053
2	NAUSEA	13621
3	NEUTROPENIA	11028
4	FEBRILE NEUTROPENIA	10932
5	VOMITING	10771
6	DISEASE PROGRESSION	10045
7	FATIGUE	9758
8	PYREXIA	9650
9	THROMBOCYTOPENIA	8251

See all common reactions for Nucleoside Metabolic Inhibitor [EPC]

Drugs of the Nucleoside Metabolic Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY	144	0.8623
1	ACUTE MYELOID LEUKAEMIA RECURRENT	503	0.4318
2	DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY	157	0.4099
3	CAECITIS	166	0.3689
4	MYELODYSPLASTIC SYNDROME TRANSFORMATION	178	0.3640
5	PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME	6117	0.3605
6	NEUTROPENIC COLITIS	402	0.3298
7	MYCOBACTERIUM CHELONAE INFECTION	154	0.3182
8	TRANSFORMATION TO ACUTE MYELOID LEUKAEMIA	126	0.3111
9	DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT	306	0.3009

See all enriched reactions for Nucleoside Metabolic Inhibitor [EPC]